| Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma RS Finn, S Qin, M Ikeda, PR Galle, M Ducreux, TY Kim, M Kudo, V Breder, ... New England Journal of Medicine 382 (20), 1894-1905, 2020 | 4691 | 2020 |
| Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial AB El-Khoueiry, B Sangro, T Yau, TS Crocenzi, M Kudo, C Hsu, TY Kim, ... The Lancet 389 (10088), 2492-2502, 2017 | 3948 | 2017 |
| Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a … H Wilke, K Muro, E Van Cutsem, SC Oh, G Bodoky, Y Shimada, ... The lancet oncology 15 (11), 1224-1235, 2014 | 2458 | 2014 |
| Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel–Lindau protein M Ohh, CW Park, M Ivan, MA Hoffman, TY Kim, LE Huang, N Pavletich, ... Nature cell biology 2 (7), 423-427, 2000 | 1944 | 2000 |
| Open versus laparoscopic surgery for mid-rectal or low-rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): survival outcomes of an open-label, non-inferiority … SY Jeong, JW Park, BH Nam, S Kim, SB Kang, SB Lim, HS Choi, DW Kim, ... The Lancet Oncology 15 (7), 767-774, 2014 | 1013 | 2014 |
| Predictive and prognostic impact of epidermal growth factor receptor mutation in non–small-cell lung cancer patients treated with gefitinib SW Han, TY Kim, PG Hwang, S Jeong, J Kim, IS Choi, DY Oh, JH Kim, ... Journal of clinical oncology 23 (11), 2493-2501, 2005 | 989 | 2005 |
| Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies TY Kim, DW Kim, JY Chung, SG Shin, SC Kim, DS Heo, NK Kim, YJ Bang Clinical cancer research 10 (11), 3708-3716, 2004 | 950 | 2004 |
| Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial T Yau, YK Kang, TY Kim, AB El-Khoueiry, A Santoro, B Sangro, I Melero, ... JAMA oncology 6 (11), e204564-e204564, 2020 | 915 | 2020 |
| Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma AL Cheng, S Qin, M Ikeda, PR Galle, M Ducreux, TY Kim, HY Lim, M Kudo, ... Journal of hepatology 76 (4), 862-873, 2022 | 731 | 2022 |
| Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours DS Hong, YK Kang, M Borad, J Sachdev, S Ejadi, HY Lim, AJ Brenner, ... British journal of cancer 122 (11), 1630-1637, 2020 | 559 | 2020 |
| Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised … C Eng, TW Kim, J Bendell, G Argilés, NC Tebbutt, M Di Bartolomeo, ... The lancet oncology 20 (6), 849-861, 2019 | 439 | 2019 |
| Lineage-dependent gene expression programs influence the immune landscape of colorectal cancer HO Lee, Y Hong, HE Etlioglu, YB Cho, V Pomella, B Van den Bosch, ... Nature genetics 52 (6), 594-603, 2020 | 431 | 2020 |
| Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy … YS Hong, BH Nam, K Kim, JE Kim, SJ Park, YS Park, JO Park, SY Kim, ... The lancet oncology 15 (11), 1245-1253, 2014 | 428 | 2014 |
| IMbrave150: updated overall survival data from a global, randomized, open-label Phase III study of atezolizumab+ bevacizumab vs sorafenib in patients with unresectable … RS Finn, S Qin, M Ikeda, PR Galle, M Ducreux, TY Kim, HY Lim, M Kudo, ... J Clin Oncol 39 (3 suppl), 267, 2021 | 332 | 2021 |
| Optimization of patient selection for gefitinib in non–small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt … SW Han, TY Kim, YK Jeon, PG Hwang, SA Im, KH Lee, JH Kim, DW Kim, ... Clinical Cancer Research 12 (8), 2538-2544, 2006 | 330 | 2006 |
| Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: randomized expansion of a phase I/II study RK Kelley, B Sangro, W Harris, M Ikeda, T Okusaka, YK Kang, S Qin, ... Journal of Clinical Oncology 39 (27), 2991, 2021 | 308 | 2021 |
| Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis B Keam, SA Im, KH Lee, SW Han, DY Oh, JH Kim, SH Lee, W Han, ... Breast Cancer Research 13, 1-7, 2011 | 297 | 2011 |
| Clinical significance of elevated level of serum antithyroglobulin antibody in patients with differentiated thyroid cancer after thyroid ablation JK Chung, YJ Park, TY Kim, Y So, SK Kim, DJ Park, DS Lee, MC Lee, ... Clinical endocrinology 57 (2), 215-221, 2002 | 270 | 2002 |
| Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the … B Keam, SA Im, HJ Kim, DY Oh, JH Kim, SH Lee, EK Chie, W Han, ... BMC cancer 7, 1-11, 2007 | 249 | 2007 |
| Nivolumab (NIVO)+ ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040. T Yau, YK Kang, TY Kim, AB El-Khoueiry, A Santoro, B Sangro, I Melero, ... Journal of Clinical Oncology 37 (15_suppl), 4012-4012, 2019 | 246 | 2019 |
